Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc.

Ocugen ( ($OCGN) ) just unveiled an announcement. On March 24, 2026, Ocugen reported positive 12‑month topline data from its Phase 2 ArMaDa trial o...

Ocugen Reports Positive Phase 2 Data for OCU410 Therapy

Analysts are intrested in these 5 stocks: ( ($TTD) ), ( ($OCGN) ), ( ($STZ) ), ( ($VRTX) ) and ( ($LCID) ). Here is a breakdown of their recent


TTD, OCGN, STZ, VRTX, LCID Trending With Analysts

Ocugen ( ($OCGN) ) has provided an update. In August 2025, Ocugen, Inc. completed a registered direct offering with an institutional investor invol...

Ocugen Gains $15 Million, Extends Cash Runway to 2027

In a report released yesterday, Whitney Ijem from Canaccord Genuity initiated coverage with a Buy rating on Ocugen and a price target of $12.00. Th...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCGN	$1.86	+6.61%	3.73M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OCGN	$1.86	+6.6%	3.73M
3
4
5
6

OCGN

OCGN

No Data Available

Get Ocugen, Inc. Data in Excel

Get Ocugen, Inc. Data in Excel